FCGR2A and COVID-19: Despite the overabundance of asymptomatic (or not reported) COVID-19, worse disease severity was associated with higher SARS-CoV-2–specific antibodies and antibody-specific FcγR binding capacity in the COVID-19+ cohort (Figure 4, B and D).